Biohaven Pharmaceutical Holding Company (BHVN +7.3%) is up, albeit on light volume, in reaction its corporate update that includes an expected FDA nod for migraine med rimegepant in Q1 2020 under Priority Review status.
The company recently filed U.S. applications for Zydis ODT and tablet formulations along with a Priority Review Voucher. The FDA does not intend to hold an advisory committee meeting on the filings so the company expects an action date in Q1 2020 (slide #6).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.